BridgeBio Strikes Collaboration with Baylor College of Medicine and Founding Affiliation with Bakar Labs

BridgeBio Pharma said it entered two new collaborations, one with Baylor College of Medicine to identify and translate cutting-edge research into potential therapies for patients with genetic diseases, and a founding affiliation with Bakar Labs, the incubator at UC Berkeley’s Bakar BioEnginuity Hub.

Photo: Neil Kumar, BridgeBio founder and CEO

Baylor College of Medicine’s unique approach to therapeutic development for genetic diseases and precision oncology integrates basic, translational, and clinical sciences. Through this collaboration, BridgeBio will work with Baylor College of Medicine to identify and translate promising innovations into potential therapies for patients with genetically driven diseases.

“In these challenging times we believe it is more important than ever to be a stalwart partner to academic institutions working to serve patient populations big and small,” said Neil Kumar, BridgeBio founder and CEO.

Bakar Labs was established by the University of California, Berkeley and QB3, UC’s research institute for innovation and entrepreneurship in the life sciences and is open to academic researchers from around the world. The Labs will host up to 50 innovative life science start-up companies seeking to advance promising research.

“Partnering with UC Berkeley and QB3 to launch Bakar Labs is a natural extension of our mission to discover, create, test, and deliver transformative medicines to as many patients as possible,” said Kumar.

The multi-disciplinary startup companies at Bakar Labs are supported by world-class facilities, resources, and expertise from industry and academia. BridgeBio intends to review discoveries, provide support to entrepreneurs, and consider possible partnership opportunities with startups focused on potential therapies for patients with genetically-driven diseases and cancers.

Author: Rare Daily Staff